Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Icu Medical (ICUI) Research & Development (2016 - 2025)

Historic Research & Development for Icu Medical (ICUI) over the last 17 years, with Q3 2025 value amounting to $21.3 million.

  • Icu Medical's Research & Development rose 106.05% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.8 million, marking a year-over-year increase of 10.49%. This contributed to the annual value of $88.6 million for FY2024, which is 383.27% up from last year.
  • According to the latest figures from Q3 2025, Icu Medical's Research & Development is $21.3 million, which was up 106.05% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, Icu Medical's Research & Development registered a high of $23.9 million during Q1 2022, and its lowest value of $10.7 million during Q1 2021.
  • Its 5-year average for Research & Development is $20.0 million, with a median of $21.9 million in 2025.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 12290.6% in 2022, then tumbled by 1721.75% in 2023.
  • Over the past 5 years, Icu Medical's Research & Development (Quarter) stood at $13.2 million in 2021, then surged by 78.08% to $23.4 million in 2022, then fell by 4.41% to $22.4 million in 2023, then fell by 0.25% to $22.4 million in 2024, then fell by 4.94% to $21.3 million in 2025.
  • Its last three reported values are $21.3 million in Q3 2025, $21.9 million for Q2 2025, and $23.3 million during Q1 2025.